The Artemisinin Combination Therapy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Artemether-Lumefantrine, Artesunate-Amodiaquine, Dihydroartemisinin-Piperaquine, Artesunate-Mefloquine, Artesunate-Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate).
The Artemisinin Combination Therapy Market in 2024 is witnessing significant growth, driven by the widespread adoption of artemisinin-based combination therapies (ACTs) as frontline treatments for uncomplicated malaria, expanding access to effective malaria treatment and contributing to malaria control and elimination efforts worldwide. ACTs combine artemisinin derivatives with partner drugs to provide rapid parasite clearance, reduce the risk of drug resistance, and improve treatment outcomes in patients with Plasmodium falciparum and Plasmodium vivax malaria infections. With endorsements from global health organizations, donor support, and regulatory approvals, ACTs have become standard-of-care treatments for malaria, replacing older antimalarial drugs and contributing to significant reductions in malaria morbidity and mortality in endemic regions. Moreover, the integration of ACT deployment strategies, surveillance systems, and community-based interventions further enhances ACT effectiveness, treatment adherence, and malaria control efforts, driving market expansion and supporting the global goal of malaria elimination.
A significant trend in the Artemisinin Combination Therapy (ACT) market is the rising preference for ACTs as the primary treatment for malaria. ACTs combine artemisinin derivatives with other antimalarial drugs, providing a synergistic effect that enhances efficacy and reduces the risk of drug resistance. With the World Health Organization (WHO) endorsing ACTs as the first-line treatment for uncomplicated malaria, there is a growing adoption of these therapies globally, driving market growth for artemisinin-based combinations.
The escalating burden of malaria and the emergence of drug-resistant strains serve as primary drivers for the Artemisinin Combination Therapy market. Malaria remains a significant public health challenge, particularly in tropical and subtropical regions, where it poses a considerable disease burden. As drug-resistant strains of the malaria parasite continue to evolve, there is an urgent need for effective treatment options. ACTs, leveraging the potent antimalarial properties of artemisinin, offer a crucial solution in combating drug-resistant malaria, thereby propelling the demand for artemisinin combination therapies.
An opportunity in the Artemisinin Combination Therapy market lies in research and development initiatives aimed at innovating novel ACT formulations. Continued investment in R&D efforts can lead to the development of improved ACT formulations with enhanced therapeutic efficacy, safety profiles, and patient adherence. Novel drug delivery systems, such as long-acting injectables, sustained-release formulations, and pediatric-friendly dosage forms, present opportunities to address existing challenges in malaria treatment, including dosing frequency, palatability, and compliance. By focusing on innovation, stakeholders can capitalize on the growing demand for ACTs and contribute to advancing malaria control and elimination efforts globally.
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Ajanta Pharma
Cipla Ltd
Desano Inc
Guilin Pharmaceutical
Hovid Berhad
Ipca Laboratories Ltd
KPC Pharmaceuticals
Novartis AG
Sanofi S.A.
Shelys Africa Pharmaceuticals Ltd
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Artemisinin Combination Therapy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Artemisinin Combination Therapy Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Artemisinin Combination Therapy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Artemisinin Combination Therapy Market Size Outlook, $ Million, 2021 to 2030
3.2 Artemisinin Combination Therapy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Artemisinin Combination Therapy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Artemisinin Combination Therapy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Artemisinin Combination Therapy Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Artemisinin Combination Therapy Market Industry
4.2 Key Market Trends in Artemisinin Combination Therapy Market Industry
4.3 Potential Opportunities in Artemisinin Combination Therapy Market Industry
4.4 Key Challenges in Artemisinin Combination Therapy Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Artemisinin Combination Therapy Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Artemisinin Combination Therapy Market Outlook By Segments
7.1 Artemisinin Combination Therapy Market Outlook by Segments
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
8 North America Artemisinin Combination Therapy Market Analysis And Outlook To 2030
8.1 Introduction to North America Artemisinin Combination Therapy Markets in 2024
8.2 North America Artemisinin Combination Therapy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Artemisinin Combination Therapy Market size Outlook by Segments, 2021-2030
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
9 Europe Artemisinin Combination Therapy Market Analysis And Outlook To 2030
9.1 Introduction to Europe Artemisinin Combination Therapy Markets in 2024
9.2 Europe Artemisinin Combination Therapy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Artemisinin Combination Therapy Market Size Outlook By Segments, 2021-2030
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
10 Asia Pacific Artemisinin Combination Therapy Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Artemisinin Combination Therapy Markets in 2024
10.2 Asia Pacific Artemisinin Combination Therapy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Artemisinin Combination Therapy Market size Outlook by Segments, 2021-2030
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
11 South America Artemisinin Combination Therapy Market Analysis And Outlook To 2030
11.1 Introduction to South America Artemisinin Combination Therapy Markets in 2024
11.2 South America Artemisinin Combination Therapy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Artemisinin Combination Therapy Market size Outlook by Segments, 2021-2030
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
12 Middle East And Africa Artemisinin Combination Therapy Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Artemisinin Combination Therapy Markets in 2024
12.2 Middle East and Africa Artemisinin Combination Therapy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Artemisinin Combination Therapy Market size Outlook by Segments, 2021-2030
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Ajanta Pharma
Cipla Ltd
Desano Inc
Guilin Pharmaceutical
Hovid Berhad
Ipca Laboratories Ltd
KPC Pharmaceuticals
Novartis AG
Sanofi S.A.
Shelys Africa Pharmaceuticals Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
The global Artemisinin Combination Therapy Market is one of the lucrative growth markets, poised to register a 9.2% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Ajanta Pharma, Cipla Ltd, Desano Inc, Guilin Pharmaceutical, Hovid Berhad, Ipca Laboratories Ltd, KPC Pharmaceuticals, Novartis AG, Sanofi S.A., Shelys Africa Pharmaceuticals Ltd
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume